NIKKEI 225
27,476.87 +91.62 (+0.33%) HANG SENG
19,567.69 -347.99 (-1.75%) CRUDE OIL
71.12 +1.86 (+2.69%) GOLD FUTURES
1,960.10 -23.70 (-1.19%) DOW
32,443.62 +206.09 (+0.64%) Bitcoin GBP
22,138.24 -518.93 (-2.29%)
Guardant Health, Inc. (GH)
| Previous close | 24.18 |
| Open | 24.50 |
| Bid | 23.93 x 900 |
| Ask | 24.00 x 800 |
| Day's range | 23.90 - 24.89 |
| 52-week range | 23.22 - 77.72 |
| Volume | |
| Avg. volume | 2,032,906 |
| Market cap | 2.481B |
| Beta (5Y monthly) | 0.86 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -5.97 |
| Earnings date | 03 May 2023 - 08 May 2023 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 55.94 |
- Zacks
Here's Why Guardant Health (GH) Looks Ripe for Bottom Fishing
Guardant Health (GH) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
- Business Wire
Guardant Health collaborates with The Ohio State University Comprehensive Cancer Center to study colorectal cancer screening adherence
PALO ALTO, Calif., March 21, 2023--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, has announced support for an investigator initiated study led and conducted by The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) to evaluate patient compliance with a blood-based test for colorectal cancer (CRC) screening. In this study, The Ohio State University Guardant Shield Colorectal Canc
- Simply Wall St.
In the wake of Guardant Health, Inc.'s (NASDAQ:GH) latest US$536m market cap drop, institutional owners may be forced to take severe actions
Key Insights Institutions' substantial holdings in Guardant Health implies that they have significant influence over...
